再生医療の日本市場2023~2027

■ 英語タイトル:Regenerative Medicine Market in Japan 2023-2027

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR76343-23)■ 発行会社/調査会社:Technavio
■ 商品コード:IRTNTR76343-23
■ 発行日:2023年9月8日
■ 調査対象地域:日本
■ 産業分野:ヘルスケア
■ ページ数:約120
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[再生医療の日本市場2023~2027]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

日本の再生医療市場 2023-2027日本の再生医療市場は、2022年から2027年の間に2億3,847万米ドル成長し、予測期間中のCAGRは15.89%で加速すると予測されます。当レポートでは、日本の再生医療市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。幹細胞治療の導入拡大、再生医療に対する政府の有利な規制、高齢化人口の増加などが市場を牽引しています。

Technavioの日本における再生医療市場は以下のように区分されます:
用途別
- 腫瘍
- 筋骨格
- 皮膚科学
- 免疫・炎症、その他

技術別
- 細胞・組織ベース
- 遺伝子治療

本調査では、今後数年間における日本の再生医療市場の成長を牽引する主な要因の一つとして、臨床試験件数の増加を挙げています。また、市場ベンダーによるM&Aの増加や、人工多能性幹細胞の開発は、市場の大きな需要につながるでしょう。

この調査レポートは、日本の再生医療市場を調査・分析したものです:
- 日本の再生医療市場規模
- 日本の再生医療市場予測
- 日本の再生医療市場産業分析

強固なベンダー分析は、クライアントが市場でのポジションを向上させることを目的としており、これに沿って、本レポートでは、Astellas Pharma Inc., Becton Dickinson and Co., CellSeed Inc., Cellusion Inc., Cyfuse Biomedical K.K., F. Hoffmann La Roche Ltd., FUJIFILM Corp., HEALIOS K.K., iHeart Japan Corp., Japan Tissue Engineering Co. Ltd., JCR Pharmaceticals Co. Ltd., MEDINET Co. Ltd., Metcela Inc., Nikon Corp., ROHTO Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Takara Bio Inc., Takeda Pharmaceutical Co. Ltd., Terumo Corp., and Yokogawa Electric Corp.などの企業情報が含まれています。また、日本の再生医療市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。
本レポートは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 日本の再生医療市場:アプリケーション別分析
7 日本の再生医療市場:技術別分析
8 顧客状況
9 推進要因・課題・動向
10 企業状況
11 企業分析
12 付録

*** レポート目次(コンテンツ)***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Country Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market Segmentation by Application
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Technology
o Exhibit 06: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 07: Parent market
o Exhibit 08: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 09: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 10: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 11: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 12: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 13: Chart on Japan: Year-over-year growth 2022-2027 (%)
o Exhibit 14: Data Table on Japan: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Regenerative medicine market in Japan 2017 – 2021
o Exhibit 15: Historic Market Size – Data Table on regenerative medicine market in Japan 2017 – 2021 ($ million)
o 4.2 Application Segment Analysis 2017 – 2021
o Exhibit 16: Historic Market Size – Application Segment 2017 – 2021 ($ million)
o 4.3 Technology Segment Analysis 2017 – 2021
o Exhibit 17: Historic Market Size – Technology Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 18: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 21: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 22: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 23: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 24: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Application
o 6.1 Market segments
o Exhibit 25: Chart on Application – Market share 2022-2027 (%)
o Exhibit 26: Data Table on Application – Market share 2022-2027 (%)
o 6.2 Comparison by Application
o Exhibit 27: Chart on Comparison by Application
o Exhibit 28: Data Table on Comparison by Application
o 6.3 Oncology – Market size and forecast 2022-2027
o Exhibit 29: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 30: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 31: Chart on Oncology – Year-over-year growth 2022-2027 (%)
o Exhibit 32: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
o 6.4 Musculoskeletal – Market size and forecast 2022-2027
o Exhibit 33: Chart on Musculoskeletal – Market size and forecast 2022-2027 ($ million)
o Exhibit 34: Data Table on Musculoskeletal – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Chart on Musculoskeletal – Year-over-year growth 2022-2027 (%)
o Exhibit 36: Data Table on Musculoskeletal – Year-over-year growth 2022-2027 (%)
o 6.5 Dermatology – Market size and forecast 2022-2027
o Exhibit 37: Chart on Dermatology – Market size and forecast 2022-2027 ($ million)
o Exhibit 38: Data Table on Dermatology – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Chart on Dermatology – Year-over-year growth 2022-2027 (%)
o Exhibit 40: Data Table on Dermatology – Year-over-year growth 2022-2027 (%)
o 6.6 Immunology and Inflammation and others – Market size and forecast 2022-2027
o Exhibit 41: Chart on Immunology and Inflammation and others – Market size and forecast 2022-2027 ($ million)
o Exhibit 42: Data Table on Immunology and Inflammation and others – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Chart on Immunology and Inflammation and others – Year-over-year growth 2022-2027 (%)
o Exhibit 44: Data Table on Immunology and Inflammation and others – Year-over-year growth 2022-2027 (%)
o 6.7 Market opportunity by Application
o Exhibit 45: Market opportunity by Application ($ million)
o Exhibit 46: Data Table on Market opportunity by Application ($ million)
• 7 Market Segmentation by Technology
o 7.1 Market segments
o Exhibit 47: Chart on Technology – Market share 2022-2027 (%)
o Exhibit 48: Data Table on Technology – Market share 2022-2027 (%)
o 7.2 Comparison by Technology
o Exhibit 49: Chart on Comparison by Technology
o Exhibit 50: Data Table on Comparison by Technology
o 7.3 Cell and tissue-based – Market size and forecast 2022-2027
o Exhibit 51: Chart on Cell and tissue-based – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Cell and tissue-based – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Cell and tissue-based – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Cell and tissue-based – Year-over-year growth 2022-2027 (%)
o 7.4 Gene therapy – Market size and forecast 2022-2027
o Exhibit 55: Chart on Gene therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Gene therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Gene therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Gene therapy – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Technology
o Exhibit 59: Market opportunity by Technology ($ million)
o Exhibit 60: Data Table on Market opportunity by Technology ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 61: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Drivers, Challenges, and Trends
o 9.1 Market drivers
o 9.2 Market challenges
o 9.3 Impact of drivers and challenges
o Exhibit 62: Impact of drivers and challenges in 2022 and 2027
o 9.4 Market trends
• 10 Vendor Landscape
o 10.1 Overview
o 10.2 Vendor landscape
o Exhibit 63: Overview on Criticality of inputs and Factors of differentiation
o 10.3 Landscape disruption
o Exhibit 64: Overview on factors of disruption
o 10.4 Industry risks
o Exhibit 65: Impact of key risks on business
• 11 Vendor Analysis
o 11.1 Vendors covered
o Exhibit 66: Vendors covered
o 11.2 Market positioning of vendors
o Exhibit 67: Matrix on vendor position and classification
o 11.3 Astellas Pharma Inc.
o Exhibit 68: Astellas Pharma Inc. – Overview
o Exhibit 69: Astellas Pharma Inc. – Product / Service
o Exhibit 70: Astellas Pharma Inc. – Key news
o Exhibit 71: Astellas Pharma Inc. – Key offerings
o 11.4 Becton Dickinson and Co.
o Exhibit 72: Becton Dickinson and Co. – Overview
o Exhibit 73: Becton Dickinson and Co. – Business segments
o Exhibit 74: Becton Dickinson and Co. – Key news
o Exhibit 75: Becton Dickinson and Co. – Key offerings
o Exhibit 76: Becton Dickinson and Co. – Segment focus
o 11.5 CellSeed Inc.
o Exhibit 77: CellSeed Inc. – Overview
o Exhibit 78: CellSeed Inc. – Product / Service
o Exhibit 79: CellSeed Inc. – Key offerings
o 11.6 Cyfuse Biomedical K.K.
o Exhibit 80: Cyfuse Biomedical K.K. – Overview
o Exhibit 81: Cyfuse Biomedical K.K. – Product / Service
o Exhibit 82: Cyfuse Biomedical K.K. – Key offerings
o 11.7 F. Hoffmann La Roche Ltd.
o Exhibit 83: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 84: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 85: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 86: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 87: F. Hoffmann La Roche Ltd. – Segment focus
o 11.8 FUJIFILM Corp.
o Exhibit 88: FUJIFILM Corp. – Overview
o Exhibit 89: FUJIFILM Corp. – Business segments
o Exhibit 90: FUJIFILM Corp. – Key news
o Exhibit 91: FUJIFILM Corp. – Key offerings
o Exhibit 92: FUJIFILM Corp. – Segment focus
o 11.9 iHeart Japan Corp.
o Exhibit 93: iHeart Japan Corp. – Overview
o Exhibit 94: iHeart Japan Corp. – Product / Service
o Exhibit 95: iHeart Japan Corp. – Key offerings
o 11.10 JCR Pharmaceticals Co. Ltd.
o Exhibit 96: JCR Pharmaceticals Co. Ltd. – Overview
o Exhibit 97: JCR Pharmaceticals Co. Ltd. – Product / Service
o Exhibit 98: JCR Pharmaceticals Co. Ltd. – Key offerings
o 11.11 Nikon Corp.
o Exhibit 99: Nikon Corp. – Overview
o Exhibit 100: Nikon Corp. – Business segments
o Exhibit 101: Nikon Corp. – Key news
o Exhibit 102: Nikon Corp. – Key offerings
o Exhibit 103: Nikon Corp. – Segment focus
o 11.12 ROHTO Pharmaceutical Co. Ltd.
o Exhibit 104: ROHTO Pharmaceutical Co. Ltd. – Overview
o Exhibit 105: ROHTO Pharmaceutical Co. Ltd. – Business segments
o Exhibit 106: ROHTO Pharmaceutical Co. Ltd. – Key offerings
o Exhibit 107: ROHTO Pharmaceutical Co. Ltd. – Segment focus
o 11.13 Sumitomo Pharma Co. Ltd.
o Exhibit 108: Sumitomo Pharma Co. Ltd. – Overview
o Exhibit 109: Sumitomo Pharma Co. Ltd. – Business segments
o Exhibit 110: Sumitomo Pharma Co. Ltd. – Key offerings
o Exhibit 111: Sumitomo Pharma Co. Ltd. – Segment focus
o 11.14 Takara Bio Inc.
o Exhibit 112: Takara Bio Inc. – Overview
o Exhibit 113: Takara Bio Inc. – Product / Service
o Exhibit 114: Takara Bio Inc. – Key offerings
o 11.15 Takeda Pharmaceutical Co. Ltd.
o Exhibit 115: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 116: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 117: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 118: Takeda Pharmaceutical Co. Ltd. – Key offerings
o 11.16 Terumo Corp.
o Exhibit 119: Terumo Corp. – Overview
o Exhibit 120: Terumo Corp. – Business segments
o Exhibit 121: Terumo Corp. – Key news
o Exhibit 122: Terumo Corp. – Key offerings
o Exhibit 123: Terumo Corp. – Segment focus
o 11.17 Yokogawa Electric Corp.
o Exhibit 124: Yokogawa Electric Corp. – Overview
o Exhibit 125: Yokogawa Electric Corp. – Business segments
o Exhibit 126: Yokogawa Electric Corp. – Key offerings
o Exhibit 127: Yokogawa Electric Corp. – Segment focus
• 12 Appendix
o 12.1 Scope of the report
o 12.2 Inclusions and exclusions checklist
o Exhibit 128: Inclusions checklist
o Exhibit 129: Exclusions checklist
o 12.3 Currency conversion rates for US$
o Exhibit 130: Currency conversion rates for US$
o 12.4 Research methodology
o Exhibit 131: Research methodology
o Exhibit 132: Validation techniques employed for market sizing
o Exhibit 133: Information sources
o 12.5 List of abbreviations
o Exhibit 134: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Country Market Characteristics
Exhibits4: Executive Summary – Chart on Market Segmentation by Application
Exhibits5: Executive Summary – Chart on Market Segmentation by Technology
Exhibits6: Executive Summary – Chart on Vendor Market Positioning
Exhibits7: Parent market
Exhibits8: Market Characteristics
Exhibits9: Offerings of vendors included in the market definition
Exhibits10: Market segments
Exhibits11: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits12: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits13: Chart on Japan: Year-over-year growth 2022-2027 (%)
Exhibits14: Data Table on Japan: Year-over-year growth 2022-2027 (%)
Exhibits15: Historic Market Size – Data Table on regenerative medicine market in Japan 2017 – 2021 ($ million)
Exhibits16: Historic Market Size – Application Segment 2017 – 2021 ($ million)
Exhibits17: Historic Market Size – Technology Segment 2017 – 2021 ($ million)
Exhibits18: Five forces analysis – Comparison between 2022 and 2027
Exhibits19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits21: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits22: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits23: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits24: Chart on Market condition – Five forces 2022 and 2027
Exhibits25: Chart on Application – Market share 2022-2027 (%)
Exhibits26: Data Table on Application – Market share 2022-2027 (%)
Exhibits27: Chart on Comparison by Application
Exhibits28: Data Table on Comparison by Application
Exhibits29: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits30: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits31: Chart on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits32: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits33: Chart on Musculoskeletal – Market size and forecast 2022-2027 ($ million)
Exhibits34: Data Table on Musculoskeletal – Market size and forecast 2022-2027 ($ million)
Exhibits35: Chart on Musculoskeletal – Year-over-year growth 2022-2027 (%)
Exhibits36: Data Table on Musculoskeletal – Year-over-year growth 2022-2027 (%)
Exhibits37: Chart on Dermatology – Market size and forecast 2022-2027 ($ million)
Exhibits38: Data Table on Dermatology – Market size and forecast 2022-2027 ($ million)
Exhibits39: Chart on Dermatology – Year-over-year growth 2022-2027 (%)
Exhibits40: Data Table on Dermatology – Year-over-year growth 2022-2027 (%)
Exhibits41: Chart on Immunology and Inflammation and others – Market size and forecast 2022-2027 ($ million)
Exhibits42: Data Table on Immunology and Inflammation and others – Market size and forecast 2022-2027 ($ million)
Exhibits43: Chart on Immunology and Inflammation and others – Year-over-year growth 2022-2027 (%)
Exhibits44: Data Table on Immunology and Inflammation and others – Year-over-year growth 2022-2027 (%)
Exhibits45: Market opportunity by Application ($ million)
Exhibits46: Data Table on Market opportunity by Application ($ million)
Exhibits47: Chart on Technology – Market share 2022-2027 (%)
Exhibits48: Data Table on Technology – Market share 2022-2027 (%)
Exhibits49: Chart on Comparison by Technology
Exhibits50: Data Table on Comparison by Technology
Exhibits51: Chart on Cell and tissue-based – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Cell and tissue-based – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Cell and tissue-based – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Cell and tissue-based – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Gene therapy – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Gene therapy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Gene therapy – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Gene therapy – Year-over-year growth 2022-2027 (%)
Exhibits59: Market opportunity by Technology ($ million)
Exhibits60: Data Table on Market opportunity by Technology ($ million)
Exhibits61: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits62: Impact of drivers and challenges in 2022 and 2027
Exhibits63: Overview on Criticality of inputs and Factors of differentiation
Exhibits64: Overview on factors of disruption
Exhibits65: Impact of key risks on business
Exhibits66: Vendors covered
Exhibits67: Matrix on vendor position and classification
Exhibits68: Astellas Pharma Inc. – Overview
Exhibits69: Astellas Pharma Inc. – Product / Service
Exhibits70: Astellas Pharma Inc. – Key news
Exhibits71: Astellas Pharma Inc. – Key offerings
Exhibits72: Becton Dickinson and Co. – Overview
Exhibits73: Becton Dickinson and Co. – Business segments
Exhibits74: Becton Dickinson and Co. – Key news
Exhibits75: Becton Dickinson and Co. – Key offerings
Exhibits76: Becton Dickinson and Co. – Segment focus
Exhibits77: CellSeed Inc. – Overview
Exhibits78: CellSeed Inc. – Product / Service
Exhibits79: CellSeed Inc. – Key offerings
Exhibits80: Cyfuse Biomedical K.K. – Overview
Exhibits81: Cyfuse Biomedical K.K. – Product / Service
Exhibits82: Cyfuse Biomedical K.K. – Key offerings
Exhibits83: F. Hoffmann La Roche Ltd. – Overview
Exhibits84: F. Hoffmann La Roche Ltd. – Business segments
Exhibits85: F. Hoffmann La Roche Ltd. – Key news
Exhibits86: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits87: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits88: FUJIFILM Corp. – Overview
Exhibits89: FUJIFILM Corp. – Business segments
Exhibits90: FUJIFILM Corp. – Key news
Exhibits91: FUJIFILM Corp. – Key offerings
Exhibits92: FUJIFILM Corp. – Segment focus
Exhibits93: iHeart Japan Corp. – Overview
Exhibits94: iHeart Japan Corp. – Product / Service
Exhibits95: iHeart Japan Corp. – Key offerings
Exhibits96: JCR Pharmaceticals Co. Ltd. – Overview
Exhibits97: JCR Pharmaceticals Co. Ltd. – Product / Service
Exhibits98: JCR Pharmaceticals Co. Ltd. – Key offerings
Exhibits99: Nikon Corp. – Overview
Exhibits100: Nikon Corp. – Business segments
Exhibits101: Nikon Corp. – Key news
Exhibits102: Nikon Corp. – Key offerings
Exhibits103: Nikon Corp. – Segment focus
Exhibits104: ROHTO Pharmaceutical Co. Ltd. – Overview
Exhibits105: ROHTO Pharmaceutical Co. Ltd. – Business segments
Exhibits106: ROHTO Pharmaceutical Co. Ltd. – Key offerings
Exhibits107: ROHTO Pharmaceutical Co. Ltd. – Segment focus
Exhibits108: Sumitomo Pharma Co. Ltd. – Overview
Exhibits109: Sumitomo Pharma Co. Ltd. – Business segments
Exhibits110: Sumitomo Pharma Co. Ltd. – Key offerings
Exhibits111: Sumitomo Pharma Co. Ltd. – Segment focus
Exhibits112: Takara Bio Inc. – Overview
Exhibits113: Takara Bio Inc. – Product / Service
Exhibits114: Takara Bio Inc. – Key offerings
Exhibits115: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits116: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits117: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits118: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits119: Terumo Corp. – Overview
Exhibits120: Terumo Corp. – Business segments
Exhibits121: Terumo Corp. – Key news
Exhibits122: Terumo Corp. – Key offerings
Exhibits123: Terumo Corp. – Segment focus
Exhibits124: Yokogawa Electric Corp. – Overview
Exhibits125: Yokogawa Electric Corp. – Business segments
Exhibits126: Yokogawa Electric Corp. – Key offerings
Exhibits127: Yokogawa Electric Corp. – Segment focus
Exhibits128: Inclusions checklist
Exhibits129: Exclusions checklist
Exhibits130: Currency conversion rates for US$
Exhibits131: Research methodology
Exhibits132: Validation techniques employed for market sizing
Exhibits133: Information sources
Exhibits134: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR76343-23 )"再生医療の日本市場2023~2027" (英文:Regenerative Medicine Market in Japan 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。